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ABSTRACT
Background: Few studies have evaluated the long-term effects of nutritional supplementation during the first 1000 d
of life. We previously reported that maternal and child lipid-based nutrient supplements (LNS) increased child length by
18 mo.
Objective: The aim of this study was to examine the effects of LNS on later growth and body composition at 4–6 y of
age.
Design: This was a follow-up of children in the International Lipid-based Nutrient Supplements (iLiNS)-DYAD trial in
Ghana. Women (n= 1320) at ≤20 weeks of gestation were randomly assigned to: 1) iron and folic acid during pregnancy
and 200 mg calcium/d for 6 mo postpartum, 2) multiple micronutrients (1–2 RDA of 18 vitamins and minerals) during
both periods, or 3) maternal LNS during both periods plus child LNS from 6 to 18 mo. At 4–6 y, we compared height,
height-for-age z score (HAZ), and % body fat (deuterium dilution method) between the LNS group and the 2 non-LNS
groups combined.
Results: Data were available for 961 children (76.5% of live births). There were no significant differences between
LNS compared with non-LNS groups in height [106.7 compared with 106.3 cm (mean difference, MD, 0.36; P = 0.226)],
HAZ [−0.49 compared with −0.57 (MD = 0.08; P = 0.226)], stunting (< -2 SD) [6.5 compared with 6.3% (OR = 1.00;
P = 0.993)], or % body fat [15.5 compared with 15.3% (MD = 0.16; P = 0.630)]. However, there was an interaction
with maternal prepregnancy BMI (kg/m2) (P-interaction = 0.046 before correction for multiple testing): among children
of women with BMI < 25 , LNS children were taller than non-LNS children (+1.1 cm, P = 0.017), whereas there was no
difference among children of women with BMI ≥ 25 (+0.1 cm; P = 0.874).
Conclusions: There was no overall effect of LNS on height at 4–6 y in this cohort, which had a low stunting rate, but
height was greater in the LNS group among children of nonoverweight/obese women. There was no adverse impact of
LNS on body composition. This trial was registered at clinicaltrials.gov as NCT00970866. J Nutr 2019;149:847–855.
Keywords: growth, body composition, lipid-based nutrient supplements, follow-up, prenatal supplementation
Introduction
Nutrition is essential for child growth and development
throughout the first 1000 d of life (conception to the child’s
second birthday) and beyond (1–3). Early childhood nutrition
has been linked to several health outcomes in later life
including obesity and chronic diseases such as type 2 diabetes,
hypertension, and cardiovascular disease (4). The relationships
of child anthropometric indices to later health may depend on
the index examined. Stunting is a risk factor for diminished
survival, learning capacity, and productivity (2, 5). On the
other hand, rapid increases in weight and BMI during the
preschool years are associated with adult obesity and altered
body composition in adolescence and adulthood (6).
Although several randomized trials have examined the
effects of nutritional supplementation in early life, very few have
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included follow-up of long-term consequences. Two landmark
trials of maternal plus child food supplementation conducted in
the 1970s included assessments several years post intervention.
In Guatemala (7), pregnant and lactating women and their
children from birth to 7 y of age received either a high-
protein, high-energy supplement called “Atole”or a nonprotein,
low-energy supplement called “Fresco,” both fortified with
micronutrients. In adolescence, children in the Atole group were
taller, heavier, and had higher fat-free mass (FFM) than those in
the Fresco group. In Colombia, there was a sustained positive
effect of maternal and child food supplementation on child
height and weight 3 y after the intervention period ended (8).
The International Lipid-based Nutrient Supplements
(iLiNS)-DYAD trial in Ghana is 1 of the first randomized trials
since the 1970s to assess the impact of combined maternal and
infant supplementation on child growth and other outcomes (9,
10). The iLiNS-DYAD trial tested the efficacy of small-quantity
lipid-based nutrient supplements for both mothers and infants,
compared with 2 other treatments for mothers only [prenatal
iron and folic acid (IFA) followed by postnatal calcium (200
mg/d) supplementation, or multiple micronutrients (MMN)
both prenatally and postnatally], with regard to pregnancy
outcomes and child growth to 18 mo of age. At birth, infants
born to women in the LNS group had significantly greater birth
weight, weight-for-age, and BMI-for-age z scores compared to
children born to women in the IFA group but not the MMN
supplement group; among infants of primiparous women,
the LNS group had greater weight and length compared to
both control groups (10). By 18 mo, there was a significant
positive effect of LNS on length, stunting prevalence, and
weight compared to the 2 control groups combined (9). Our
objective herein is to examine the effect of maternal and
infant supplementation with LNS on child growth and body
composition at 4–6 y of age in the iLiNS-DYAD Ghana cohort.
Methods
Location and study design of the main trial
The iLiNS-DYAD Ghana trial was conducted in the Yilo and Lower
Manya Krobo districts of the Eastern Region of Ghana between
December 2009 and March 2014. Details of the study are published
elsewhere (10). Briefly, the iLiNS-DYAD study was a partially double-
blind randomized controlled trial which enrolled 1320 women aged
≥18 y at ≤20 weeks of gestation attending antenatal clinics in 4 main
health facilities in the study area. The women were randomized to 1 of
3 treatments: (1) daily IFA tablets during pregnancy and a 200 mg/d
calcium tablet (placebo) during the first 6 mo postpartum and no infant
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supplementation, (2) daily MMN tablets (1–2 RDA of 18 vitamins
and minerals) during pregnancy and the first 6 mo postpartum and no
infant supplementation, or (3) daily 20 g (118 kcal) lipid-based nutrient
supplements (LNS) during pregnancy and the first 6 mo postpartum
followed by infant 20 g/d LNS supplementation from 6 to 18 mo of age.
The maternal LNS had the same micronutrient content as the MMN,
plus calcium, magnesium, phosphorus, potassium, and macronutrients
(essential fatty acids and a small amount of protein), and the infant LNS
had the same macronutrients and 22 micronutrients based on infant
Recommended Nutrient Intakes (11). Data collection in the main trial
ended for women at 6 mo postpartum and for the children at 18 mo
of age.
Follow-up when children were 4–6 y of age
After themain trial ended in 2014, an update of contact informationwas
undertaken in preparation for a future follow-up study. The follow-up
study occurred in 2016 when the children were 4–6 y of age.
Participants at follow-up.
For the follow-up at 4–6 y of child’s age, we sought to locate all children
born to pregnant women who had been randomized to 1 of the 3
intervention groups of the iLiNS-DYAD trial, regardless of whether
their mothers were lost to follow-up before delivery or they themselves
or their mothers were lost to follow-up after delivery and before the
end of the main trial. Excluding misdiagnosed pregnancies (n = 5),
miscarriages, and stillbirths (n = 66), and children who died before the
end of the main trial (n = 27), 1222 children were potentially eligible to
participate. Details of participant enrollment and eligibility are shown
in Figure 1.
The follow-up study protocols were approved by the Institutional
Review Boards of the University of California, Davis, the Ethics
Committee for the College of Basic and Applied Sciences at the
University of Ghana, and the Ghana Health Service Ethical Review
Committee. Both the main trial and follow-up were registered at
clinicaltrials.gov as NCT00970866. Written informed consent was
given by the primary caregiver before data collection.
Data collection procedures.
Before data collection for the follow-up began, we conducted a
pilot study using the deuterium dilution method to determine the
equilibration time for a deuterium dose in 4–6-y-old children. The pilot
study followed the procedures outlined by the International Atomic
Energy Agency for determination of total body water (TBW) using a
Fourier transform infrared spectrometer (12). The sample size for the
pilot study was 15 children. The children consumed a dose of deuterium
based on their body weight. No adverse effects of deuterium oxide at
this amount have been reported in humans (12). Saliva samples were
collected at baseline before the dose, 2 h after the dose, and every 30
min until 4 h after the dose was given. Data were analyzed by plotting
a graph of mean deuterium concentration against time of post-dose
sample collection, which showed a plateau between 2.5 h and 3.5 h.
To determine the equilibration time, we calculated each child’s % CV
for deuterium enrichment for each pair of time points, between 2 h and
2.5 h, 2.5 h and 3 h, 3 h and 3.5 h, and 3.5 h and 4 h. Equilibration is
considered to have occurred when the % CV is ≤2% (12). The mean
% CV was 1.46, 0.61, 0.74, and 1.77 for the 2 h and 2.5 h, 2.5 h and 3
h, 3 h and 3.5 h, and 3.5 h and 4 h time points, respectively. Based on
this analysis, we chose 2.5 h and 3 h after dose administration as the
equilibration times to be used in the follow-up study.
For the follow-up, data collection was done at a central location.
We used Open Data Kit software and programmed our questionnaires
on tablets (13) with quality checks built into the system to minimize
entry of implausible values. A questionnaire was administered to update
information provided at enrollment into the main trial. Anthropometric
measurements were taken by 2 anthropometrists who had been trained
to take similar measurements in the main trial, 1 of whom was
considered the “gold standard” for standardization sessions. The
anthropometrists were retrained and standardized at the beginning of
data collection and every quarter until the end of data collection (14).
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1575 recruited 
1320 enrolled into main 
trial 
>20 weeks gestation (197) 
Refusal by woman (24) 
Loss of pregnancy (9) 
Misdiagnosed pregnancy (9) 
Acute illness (8) 
Moved/planned to move (2) 
Other (6) 
Randomly Assigned  
IFA 
n = 441 
MMN 
n = 439 
LNS 
n = 440 
Targeted for follow-up 
n = 854 
Targeted for 
follow-up 
n = 424 
Eligible for re-enrollment at age 4-6y 
n = 817 
Eligible for  re-
enrollment at age 4-6y 
n = 405 
Re-enrolled at age 4-6y 
n = 662 
Re-enrolled 
at age 4-6y 
n = 352 
Children measured 
n = 623 
Children 
measured 
n = 338 
Misdiagnosed 
pregnancy (n = 4) 
Miscarriage 
(n = 12) 
Misdiagnosed 
pregnancy 
(n = 1) 
Miscarriage 
(n = 25)
Still birth 
(n = 22) 
Child died 
(n = 15) 
Still birth (n = 7) 
Child died 
(n = 12) 
Not traced (n = 65) 
Refused (n = 35) 
Child died after 
main trial (n = 3) 
Moved (n = 52) 
Not traced (n = 31) 
Refused (n = 8) 
Child died after 
main trial (n = 2) 
Moved (n = 12) 
Lost to follow-
up (n = 39) 
Lost to follow-
up (n = 14) 
FIGURE 1 Study profile of the International Lipid-Based Nutrient Supplements (iLiNS)-DYAD Ghana trial. IFA, iron folic acid; LNS, lipid-based
nutrient supplement; MMN, multiple micronutrients.
Height was measured using a stadiometer (Seca 217) to 0.1 cm,
weight to the nearest 50 g (Seca 875 scale),midupper arm circumference
(MUAC) to the nearest 0.1 cm using a Shorr tape, and triceps skinfolds
(TSF) to 0.2 mm with Lange calipers according to WHO standard
procedures (15). All measurements were taken in duplicate and in
triplicate if the first 2 measurements differed by a predefined amount:
0.1 kg for weight, 0.5 cm for height and MUAC, and 2 mm for TSF.
For TBW determination, children were given a dose of deuterium
based on weight. Children <20 kg received a 6 g dose, whereas those
≥20 kg were given a 10 g dose as recommended by the International
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Atomic Energy Agency (12). All doses were prepared in bulk as a 1 in 5
dilution. If the child had been sick (defined as fever, cold, cough,malaria,
hospitalization) in the previous 7 d before the day of data collection, the
TBW assessment was rescheduled. Because the children were young, we
required that all children be given breakfast before they came for sample
collection, and the dose was administered at least 2 h after breakfast.
A snack (150 g of a chocolate drink and a packet of biscuits) of
<300 kcal was also provided 1 h after the dose to standardize what
they were offered. Any leftovers were weighed and recorded. Saliva
samples were stored in a −33◦C freezer and transported in ice chests to
the laboratory at the Ghana Atomic Energy Commission for analysis.
Each sample was measured in duplicate and the mean deuterium
concentration for each time point was calculated. Each morning and
at different times during the sample analysis, performance of the
equipment was checked by running quality control samples.
Percent CV was calculated using the means of the 2.5 h and 3 h
time points. If the % CV was >5%, samples were rerun and if sample
volume was not sufficient for the rerun or the % CV remained >5%,
only the enrichment at 3 h was used in the calculation of TBW. For
subjects without the 3 h sample, enrichment at 2.5 h was used in the
calculation of TBW.
To determine TBW, the average of the means at 2.5 and 3 h was
taken and used together with the amount of dose administered and
dilution space of the body in the calculation of TBW. Where there was
only a value for 1 time point, that value was used to calculate TBW.
FFMwas then calculated from TBW and age- and sex-specific hydration
factors (12). The difference between body weight and FFM gives fat
mass (FM).
Anthropometrists, field staff, and laboratory staff were blinded to
the group assignments. The data analyst remained blinded until all
decisions regarding outliers had been made.
Sample size and data analysis.
We hypothesized that (a) children in the LNS group would differ
in height and HAZ compared to children in the combined IFA and
MMN tablet group at 4–6 y, and (b) children in the LNS group
would not have significantly higher % body fat compared to the
children in the combined IFA and MMN tablet (non-LNS) group at
4–6 y (noninferiority analysis). For the second hypothesis, we chose a
noninferiority approach because our objective was to rule out potential
adverse effects (i.e., greater body fatness in the LNS group), given
concerns that a high-fat product might lead to greater body fatness,
and we prespecified a noninferiority margin of 1% in body fat, based
on a SD of 2.6% in fat mass (16) and the aim of ruling out any effect
greater than a moderate effect size of 0.4 (noninferiority margin divided
by SD). Noninferiority was established if the difference in the means
and the CI around it were below the predetermined margin of inferiority
(where lower is better). Both hypotheses were based on combining the 2
control groups (IFA andMMN), as there was no evidence of differences
in growth or body composition in other studies comparing MMN
to IFA (17). Nevertheless, a sensitivity analysis was also performed
comparing the 3 groups to check for any differences between the IFA
andMMN groups. Primary outcomes were height (cm), height-for-age z
score (HAZ) and% FM at 4–6 y. Secondary outcomes included stunting
(HAZ < -2), weight (kg), weight-for-age z score (WAZ), underweight
(WAZ < -2), overweight (BMIZ > +1), arm fat area (AFA), arm muscle
area (AMA), and high body fat. AFA and AMA were calculated using
the following equations:
AFA(cm2) = (TSF X MUAC/2) − (π X(TSF)2/4)
AMA(cm2) = [(MUAC − (π X TSF))]2/4π (1)
where TSF and MUAC are in cm (18).
High body fat was defined as % body fat ≥20. About half the
children in our sample were <5 y of age, and we could not find
a reference for high body fat for children aged <5 y. There are
documented sex differences in %FM after 5 y of age (19), but it
is not clear whether a sex difference is generally found in children
aged <5 y, or the magnitude of any such difference. Because of this
uncertainty we were unable to use sex-specific cutoffs for %FM, and
instead chose a somewhat arbitrary cutoff (20%) that was in between
the 85th percentile reference values for boys and girls 5–6 y of age [85th
percentile, 18.6% and 19.5% for 5-y-old and 6-y-old boys, and 21.5%
and 23.0% for 5-y-old and 6-y-old girls, respectively] (19) and coincided
with the 85th percentile in our sample.
The sample size for the primary outcome of height was based on
detecting an effect size, Cohen’s d (20), of ≥0.25 in mean height. This
resulted in a minimum sample size of 198 per group to detect the
difference with 80% power and α = 0.05. (16) Our goal, however,
was to measure all of the children we could locate, which provided
sufficient power to test our second hypothesis regarding % body fat,
and to evaluate other secondary outcomes within this longitudinal
cohort.
A statistical analysis plan was posted on the iLiNS Project website
(www.ilins.org) before data analysis. Analysis was carried out based on
a complete case intention-to-treat principle using SAS version 9.4. All
tests except the noninferiority hypothesis were 2-sided at a 5% level of
significance.
All continuous data were examined by univariate analysis to
identify outliers. The TSF, AMA, and AFA variables were not normally
distributed, therefore they were log-transformed.
ANCOVA was used to analyze the data testing the null hypothesis
of no difference in means for continuous variables. All models included
child age at follow-up. Fully adjusted models were also adjusted for
a set of prespecified potential covariates. In addition to child age, the
potential covariates included: sex of child, maternal gestational age at
enrollment, nulliparity, maternal education and estimated prepregnancy
BMI at enrollment (9), maternal height and asset score (21). The binary
outcomes were analyzed using logistic regression first by running the
unadjusted model, and then the adjusted model using the prespecified
covariates. For all analyses, only covariates significantly associated with
the outcome at 10% level of significance in a bivariate analysis were
included in the final adjusted analysis, except for child age which was
included in all models. We also tested for interaction with a set of
prespecified covariates (maternal height, estimated prepregnancy BMI,
nulliparity at enrollment, total years of schooling, and child sex). The
test for interaction was considered significant at P-interaction <0.10.
We conducted further analysis by stratifying the intervention groups
(non-LNS compared with LNS) by categories of the significant effect
modifier.
For the noninferiority hypothesis regarding % body fat, ANCOVA
was used to analyze the data. The difference in the means of the 2 groups
and associated 95% CI was compared with the predetermined margin
of inferiority (1% in body fat).
Results
Of the 1222 children who were eligible to participate in the
follow-up,we enrolled 662 in the non-LNS group and 352 in the
LNS group (Figure 1). By the end of the data collection period
(January to December 2016), we were able to measure 79%
of the eligible children, 623 in the non-LNS group and 338 in
the LNS group. The reasons for nonparticipation in the follow-
up were inability to trace the mother (n = 96), consent refusal
(n= 43), child death after the main trial ended (n= 5), no longer
residing in the study area (n = 64), and loss to follow-up after
enrollment in the follow-up (n = 53). The proportion lost to
follow-up was 23.7% in the non-LNS group and 16.5% in the
LNS group (P = 0.005).
Table 1 shows the background characteristics at enrollment
into the main trial of women whose children were enrolled into
the follow-up. More than 90% of the women were married
or cohabiting, a third were nulliparous at baseline, and 10.9%
were underweight (BMI < 18.5 kg/m2). Of the eligible children
from the main trial, maternal baseline characteristics for those
included in this follow-up (n = 961) were not significantly
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TABLE 1 Background characteristics at enrollment into the
main trial of women whose children were eligible for follow-up,
and children in the International Lipid-Based Nutrient
Supplements (iLiNS)-DYAD Ghana trial at follow-up1
Characteristic
Non-LNS
(n= 623) LNS (n= 338)
Maternal characteristics
Age, y 26.8 ± 0.2 26.8 ± 0.3
Gestational age at enrollment, wk 16.1 ± 3.2 16.1 ± 3.3
Formal education, y 7.6 ± 3.4 7.6 ± 3.8
Married or cohabiting, % 93.7 92.6
Asset score2 0.07 ± 0.95 −0.09 ± 0.983
Primiparous women, % 31.9 32.5
Weight, kg 61.7 ± 0.5 62.9 ± 0.7
Height, cm 158.9 ± 5.8 159.2 ± 5.4
Prepregnancy BMI4,5, kg/m2 24.5 ± 4.7 24.9 ± 4.5
Overweight (BMI ≥ 25), % 30.4 34.1
Underweight (BMI < 18.5), % 13.1 6.9
MUAC4, cm 27.8 ± 4.2 28.3 ± 4.3
TSF4, mm 18.7 ± 7.4 19.4 ± 7.5
Child characteristics
Age of child at follow-up, y 4.9 ± 0.6 5.0 ± 0.6
Sex of child, % boys 47.7 48.6
1Values are mean ± SD unless otherwise stated. LNS, lipid-based nutrient
supplements group; MUAC, midupper arm circumference; non-LNS, iron folic acid
group + multiple micronutrients group; TSF, triceps skinfold.
2Household asset score was constructed based on ownership of a set of assets (radio,
television, refrigerator, and stove), lighting source, drinking water supply, sanitation
facilities, and flooring materials, developed into an index (with a mean of 0 and SD of
1) using principal components analysis.
3Different from control, P < 0.05.
4Data available for less than the full sample. Sample size for these analyses of 611
compared with 334 (non-LNS compared with LNS) for weight, BMI, MUAC, and TSF
because some of the women did not have baseline anthropometric data.
5Estimated prepregnancy BMI was calculated from estimated prepregnancy weight
(based on polynomial regression with gestational age, gestational age squared, and
gestational age cubed as predictors) and height at enrollment.
different from those of children who were not in the follow-
up, except for nulliparity (32.2% among those included in
the follow-up sample compared with 38.3% among those not
included, P = 0.041, Supplemental Table 1). Among those
included in the follow-up, there were no significant differences
in background characteristics between the non-LNS and LNS
groups (Table 1), except in household asset score, which was
higher in the non-LNS group (P = 0.017). At follow-up, the
mean age (mean ± SD) of the children was 4.9 ± 0.6 y and the
percentage of boys in the sample was 48%, and these did not
differ between groups.
The means ± SD for height, HAZ, weight, WAZ, BMIZ,
and %FM in this cohort were 106.5 ± 5.5 cm, −0.54 ± 0.95,
16.6 ± 2.2 kg,−0.71 ± 0.86,−0.56 ± 0.83, and 15.4 ± 4.9%,
respectively. Table 2 shows the continuous unadjusted anthro-
pometric measures and body composition results.At 4–6 y, there
were no significant differences between the children in the non-
LNS compared with LNS groups for any of these outcomes.
In the 3-group analysis, we also did not find any significant
overall group differences or pairwise differences between the
IFA and MMN groups (Supplemental Table 2); for the primary
outcome, height, the mean ± SE values were 105.9 ± 0.3 cm,
106.6 ± 0.3 cm, 106.7 ± 0.2 cm for the IFA, MMN, and LNS
groups, respectively (P = 0.075).
The results for the noninferiority analysis indicate that
children in the LNS group did not have higher % body fat
compared with children in the non-LNS group: the upper end
of the CI for the difference in means between the 2 groups
(+0.81% body fat, Table 2) did not exceed our predetermined
inferiority margin of 1%.
The binary anthropometric outcomes are presented in
Table 3. Overall prevalence of stunting (6.4%) was low, few
children were overweight (2.9%), and 16.1% had high body
fat (≥20%). There were no significant differences between
intervention groups in any of the binary outcomes in either
the 2-group (Table 3) or 3-group (Supplemental Table 3)
comparisons.
Adjustment for prespecified covariates did not alter any of
the above findings (data not shown).
We examined potential effect modification by maternal
height, BMI, primiparity, total years of schooling, and child sex.
We found interactions (P-interaction <0.10, before correction
using the Benjamini-Hochberg procedure) of intervention group
with estimated maternal prepregnancy BMI for child height
(Figure 2), HAZ, and % fat mass, and with maternal height
for child % fat mass. For the interactions with maternal
prepregnancy BMI, height was greater in the LNS group
compared with the non-LNS group (+1.1 cm; 95% CI: 0.2, 2.1
cm, P= 0.017) among children whose mothers had a BMI < 25
kg/m2 (n = 565) at baseline, but there was no difference (+0.1
cm; 95% CI: −1.1, 1.3 cm, P = 0.874) among children of
overweight mothers (BMI ≥ 25 kg/m2; n = 380) (Figure 2).
A similar trend was observed for child HAZ: +0.19 (95% CI:
0.03, 0.35, P = 0.018) in the LNS group among children of
mothers with BMI < 25 kg/m2, and no effect of LNS (−0.10;
95% CI −0.03, 0.11, P = 0.349) among children of overweight
mothers. We did not observe a difference in % fat mass
between the non-LNS and LNS groups when we stratified by
maternal BMI (Figure 3), although P-interaction was 0.037. The
interaction of intervention group with maternal height, with
regard to child % fat mass (Supplemental Figure 1), was similar
to the pattern shown with maternal BMI. However, none of
the P-for-interaction values was significant after correction for
multiple comparisons using the Benjamini/Hochberg procedure.
Discussion
In this follow-up of the iLiNS-DYAD Ghana cohort, we did not
observe any overall effect of LNS provided to mothers during
pregnancy and the first 6 mo postpartum and to their children
from 6 to 18 mo of age on child height, HAZ, or any of the
other anthropometric measures at 4–6 y of age. Although there
were significant differences in mean length (0.61 cm; P= 0.001)
and weight (210 g; P = 0.010) between the LNS and non-
LNS groups at 18 mo (9), these differences were not sustained
several years later. However, in prespecified subgroup analyses,
the results suggested that maternal BMI may have modified the
effect of the intervention: among children of women who were
not overweight at baseline, child height was +1.1 (95% CI:
0.2, 2.1) cm greater in the LNS group compared with the non-
LNS group at 4–6 y, whereas there was no difference between
intervention groups among children of overweight women.
The noninferiority results support our hypothesis that
provision of LNS in early life did not increase % body fat at 4–
6 y of age in the overall cohort. There was evidence suggesting
effect modification bymaternal prepregnancy BMI,with slightly
greater % body fat in the LNS (compared with non-LNS)
group among children of women who were not overweight at
baseline, but slightly lower % body fat in the LNS (compared
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TABLE 2 Anthropometric and body composition measurements of children in the International Lipid-Based Nutrient Supplements
(iLiNS)-DYAD Ghana trial at 4–6 y1
Variable Non-LNS (n= 623) LNS (n= 338) P-value Difference in mean (95% CI)
Ratio of the geometric
mean (95% CI)
Height, cm 106.3 ± 0.2 106.7 ± 0.2 0.226 0.36 (−0.23, 0.95) —
Height-for-age z score −0.57 ± 0.04 −0.49 ± 0.05 0.226 0.08 (−0.05, 0.21) —
Weight, kg 16.5 ± 0.1 16.7 ± 0.1 0.214 0.17 (−0.10, 0.43) —
Weight-for-age z score −0.74 ± 0.03 −0.67 ± 0.05 0.252 0.07 (−0.05, 0.18) —
BMI-for-age z score −0.58 ± 0.03 −0.55 ± 0.05 0.606 0.03 (−0.08, 0.14) —
MUAC, cm 15.4 ± 0.1 15.5 ± 0.1 0.382 0.07 (−0.09, 0.23) —
TSF2, mm 7.0 (6.9, 7.1) 7.1 (6.9, 7.2) 0.392 — 1.01 (0.98, 1.04)
AFA 2, cm2 5.4 (5.3, 5.5) 5.5 (5.3, 5.6) 0.399 — 1.01 (0.98, 1.05)
AMA 2, cm2 13.7 (13.6, 13.9) 13.7 (13.6, 14.0) 0.891 — 1.00 (0.98, 1.02)
FM 3, kg 2.6 ± 0.0 2.6 ± 0.1 0.491 0.05 (−0.08, 0.17) —
% FM 3,4 15.3 (15.0, 15.7) 15.5 (14.9, 16.0) 0.630 0.16 (−0.49, 0.81) —
FFM 3, kg 14.0 ± 0.1 14.1 ± 0.1 0.389 0.10 (−0.13, 0.34) —
% FFM 3 84.9 (84.4, 85.3) 84.6 (84.0, 85.2) 0.429 −0.29 (−1.02, 0.43) —
1Values represent mean ± SE and the difference in mean (95% CI) unless otherwise stated. Results are based on ANCOVA (SAS PROC GLIMMIX). AFA, arm fat area; AMA, arm
muscle area; FFM, fat-free mass; FM, fat mass; LNS, lipid-based nutrient supplements group; MUAC, midupper arm circumference; non-LNS, iron folic acid group + multiple
micronutrients group; TSF, triceps skinfold.
2Values are geometric means (95% CI) and ratio of the geometric mean (95% CI). n = 622 compared with 337 (non-LNS compared with LNS).
3Values are based on less than the full sample for FM and %FM (599 compared with 326, non-LNS compared with LNS) and for FFM and %FFM (604 compared with 327,
non-LNS compared with LNS) because some participants did not take part in the body composition procedure, there was insufficient sample for analysis, or there were data
collection or lab issues.
4An outlier in the %FM variable was truncated using the value representing the 95th percentile of the distribution to make the distribution more normal.
with non-LNS) group among children of overweight women.
Because the difference between intervention groups was not
significant in either of these subgroups, we cannot conclude that
there were any positive or negative effects, although Figure 3
suggests that LNS eliminated the differential between children
of nonoverweight and overweight mothers: % body fat in the
LNS group was similar across both subgroups, whereas in the
non-LNS group % body fat was 1.5% higher in the subgroup
of children born to overweight mothers. The overall percentage
of children with high body fat (≥20%) was 16.1%,which is not
excessive given that the cutoff was based on the 85th percentile
of the reference population (19).
A strength of our study is the use of the deuterium dilution
method to determine body composition, although 2 limitations
of our procedures should be noted: we did not have an
objective measure of health before the deuterium dilution
sample collection, which is desirable because health status
influences body water, and the children were not required to fast
because this is difficult for children at this age. Another strength
is that we used trained and standardized anthropometrists
who were blinded to group assignment and all measurements
were done at a central site. Overall, we were able to measure
79% of the children born during the main trial who had
not died, with most of the loss to follow-up attributable to
relocation of participant households. A potential limitation
is the observed differential loss to follow-up between the
groups, with a higher loss in the non-LNS group. Despite
this differential loss, the groups did not differ in maternal
background characteristics (except in asset score which was
lower in the LNS group), and adjustment of the statistical
models for background characteristics did not change any of our
conclusions. In addition, the sample of children included in the
follow-up did not differ in maternal background characteristics
compared to the full sample of women enrolled in the main
trial (except for primiparity), indicating that the results could
be generalizable to the study population.
To our knowledge, only 2 previous studies included a follow-
up assessment of growth of children exposed to a nutritional
supplement during both prenatal and postnatal life, both of
which were conducted in the 1970s: the Institute of Nutrition
TABLE 3 Prevalence of underweight, stunting, overweight, and % body fat ≥20% among children in the International Lipid-Based
Nutrient Supplements (iLiNS)-DYAD Ghana trial at 4–6 y1
Non-LNS (n= 622) LNS (n= 338) OR (95% CI) P-value
Stunting (HAZ < -2 SD) — — —
Prevalence, % 6.3 6.5 1.00 (0.58, 1.73) 0.993
Underweight (WAZ < -2SD) — — —
Prevalence, % 5.6 6.2 1.10 (0.63, 1.93) 0.730
Overweight (BMIZ > 1 SD) — — —
Prevalence, % 2.9 3.0 1.10 (0.47, 2.54) 0.827
Body fat ≥20% — — —
Prevalence 2, % 14.3 17.4 1.26 (0.87, 1.18) 0.218
1Values are the percentage of participants whose response was “yes” for the outcome in question and OR (95% CI) obtained by comparing the groups. Reference = non-
LNS group for all outcomes. Results are based on logistic regression (SAS PROC GLIMMIX). BMIZ, BMI-for-age z score; HAZ, height-for-age z score; LNS, lipid-based nutrient
supplements group; non-LNS, iron folic acid group + multiple micronutrients group; WAZ, weight-for-age z score.
2Values are based on less than the full sample for overweight (601 compared with 328, non-LNS compared with LNS) because some participants did not take part in the body
composition procedure, there was insufficient sample for analysis, or there were data collection or lab issues.
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FIGURE 2 Child height at 4–6 y by intervention group (LNS
compared with non-LNS), stratified by maternal BMI at enrollment
into the International Lipid-Based Nutrient Supplements (iLiNS)-DYAD
Ghana trial. Values represent mean (95% CI) from an ANCOVA
model (SAS PROC GLIMMIX). P-interaction between estimated
maternal prepregnancy BMI as a continuous variable and intervention
group = 0.046, before Benjamini/Hochberg correction, adjusting for
maternal height, years of education, nulliparity, asset score, and child
sex. LNS, lipid-based nutrient supplements group; non-LNS, iron-folic
acid group + multiple micronutrients group.
of Central America and Panama (INCAP) longitudinal study in
Guatemala (7) and the Bogotá study of Malnutrition, Diarrheal
Disease and Child Development in Colombia (8). In both
studies, children in the intervention group were taller and
weighed more than those in the control group at the end of
the supplementation period, as was the case in our study as
well. At follow-up, both of the early trials reported sustained
effects. Although we did not find a significant overall difference
between the non-LNS and LNS groups at 4–6 y, there was a
nonsignificant difference of 0.8 cm in height between the IFA
and LNS groups, similar to the ∼ 0.6 cm difference between
these 2 groups at 18 mo (9), and a significant+1.1 cm difference
in height between the non-LNS and LNS groups among children
of women who were not overweight. The Bogotá trial showed
a difference in height of 2.3 cm at 6 y of age, 3 y after the
FIGURE 3 Child % fat mass at 4–6 y by intervention group (LNS
compared with non-LNS), stratified by maternal BMI at enrollment
into the International Lipid-Based Nutrient Supplements (iLiNS)-DYAD
Ghana trial. Values represent mean (95% CI) from an ANCOVA
model (SAS PROC GLIMMIX). P-interaction between estimated
maternal prepregnancy BMI as a continuous variable and intervention
group = 0.037, before Benjamini/Hochberg correction, adjusting for
nulliparity and child sex. LNS, lipid-based nutrient supplements group;
non-LNS, iron-folic acid group + multiple micronutrients group.
intervention ended. In the INCAP trial, mean height in the
Atole group during adolescence was 1.2 and 2.1 cm greater for
males and females, respectively, compared to the Fresco group
(the difference was significant only in females). In the earlier
trials, the supplementation period extended from pregnancy
until at least 3 y of age, whereas supplementation in our trial
ended at 18 mo. The types of supplement provided also differed
substantially among trials. We provided small-quantity LNS,
which provided a similar amount of energy per serving as
Atole but less protein. The INCAP trial provided a low-energy
fortified supplement to mothers and children in the control
group, whereas we provided IFA or MMN to mothers only.
The Bogotá trial provided 623 kcal and 30 g protein to each
family member and 856 kcal and 38 g protein to the mother
daily from week 26 of pregnancy until 36 mo postpartum; the
control group received no supplement. The supplements in the
Guatemala and Bogotá trials provided more milk than the LNS:
at least 20 g of dry milk per serving of Atole in Guatemala
(22) and 60 g/d of dry skimmed milk for each household
member in Bogotá (8), compared to 4.8 g/d of dry milk
from LNS (11). Milk and milk products have been associated
with increased linear growth, although the exact mechanism
is not known (23). Another difference between these earlier
trials and the iLiNS-DYAD Ghana trial is that malnutrition
was greater in Guatemala and Colombia at that time, when
these lower income countries had a high disease burden, poor
access to health care, and poor sanitation, whereas our study
population in Ghana had good access to health care and potable
water, most of the population had access to improved toilet
facilities, and the prevalence of overweight among the mothers
at enrollment was high (38.5%). This may explain in part why
we saw long-term effects on height only in the group of children
born to women who were not overweight. Among children of
overweight women, there is likely to be less constraint on the
growth of the child because of maternal nutrition (especially in
utero), and thus little potential to benefit from LNS, whereas
children of nonoverweight mothers may have more potential
to benefit from nutritional supplementation as evidenced in a
vulnerable Bangladeshi population (24).
Apart from the 2 trials described above, there have been
several follow-up studies of food or nutrient supplementation
during pregnancy only. A 2015 review and meta-analysis of
energy-protein supplementation trials conducted between 1973
and 2014 (25) found no sustained effects of prenatal energy-
protein supplementation alone on child growth status at 12 mo
of age (26–28) or on height, weight, and body fat at 11–17 y
(29).
In another systematic review and meta-analysis of follow-
up studies of prenatal micronutrient supplementation trials, the
meta-analysis showed no difference between groups receiving
prenatal MMNs compared with iron (60 mg) and folic acid
in child HAZ or WAZ (17). Two of the trials mentioned, 1 in
Burkina Faso (30) and the other in Nepal (31, 32) both reported
greater WAZ in the MMN groups at younger ages (1 and 2.5 y),
but these differences were not sustained at older ages (2.5 and
8.5 y, respectively). In a separate trial in Nepal (33), there was an
increase in mean height in 1 of the intervention groups (vitamin
A + iron + folic acid + zinc) compared to the control group
(vitamin A alone), but this difference was not evident in the
group whose mothers received multiple (>4) micronutrients.
The 2 Nepal trials – Janakpur (31, 32) and Sarlahi (33) – and 1
trial in Bangladesh, MINIMat (34), included measurement of
body composition. The MINIMat trial showed no difference
in skinfold thicknesses, whereas the Sarlahi Nepal trial showed
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lower skinfold thickness in 1 intervention group (iron + folic
acid + zinc) compared to controls at 7.5 y, and the Janakpur
Nepal trial showed higher TSF in the MMN group at 2.5 y but
not later. There was no reported difference in lean mass or fat
mass in either the MINIMat or Janakpur Nepal studies. These
findings are consistent with our findings from the follow-up of
the iLiNS-DYAD Ghana trial of no differences between the IFA
and MMN groups.
We conclude that there was no overall effect of LNS on
height or HAZ at 4–6 y of age in this cohort, which had
a low stunting rate, but the results suggested an increase
in height and HAZ in the LNS group among children of
nonoverweight women. Although this finding needs to be
confirmed in similar populations, it has potential implications
for targeting interventions such as LNS. There was no adverse
impact of LNS on child body fatness, suggesting that a small
daily quantity of a high-fat fortified supplement in early life does
not contribute to child overweight.
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